(原标题:国证国际:给予中国头部疫苗企业艾美疫苗(06660.HK)买入评级)国证国际发布研报称,艾美疫苗作为我国头部疫苗企业,拥有 8 款商业化产品和 22 款在研疫苗,且未来三年预计每年将有 1-2 款产品上市。若在研产品陆续成功获批上市,同时产品出海进展顺利,有望为公司带来新的业绩增长点并打开市场天花板。研报给予公司2026年3.6倍PS的估值,并给予"买入"评级。研报指出,艾美疫苗生产的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.